VEGFA and wet macular degeneration: [1], [2] AMD can be classified into two groups: ‘dry’ (atrophic) and ‘wet’ (neovascular) AMD. Dry AMD accounts for approximately 90% of cases of AMD, [3] and is characterized by primary loss of the retinal pigment epithelium (RPE) with secondary atrophy of the overlying photoreceptors and underlying choriocapillaris. Vascular endothelial growth factor (VEGF) inhibitors have provided a breakthrough in the treatment of wet AMD. [4] However there is currently no effective treatment for dry AMD.